Potential False Positives Abbott Alinity m SARS-CoV-2 AMP and m Resp-4-Plex AMP Kits

Read the letter to learn about more the FDA's recommendations and instructions for reporting problems with the Abbott Alinity kits

If your email program has trouble displaying this email, view as a webpage. Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits Today, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to alert clinical laboratory staff and health care providers about the potential for false positive results with Abbott Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits. Read More The Letter to Health Care Providers includes important information about Abbott Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits including, Details on potential false positive results. Recommendations for clinical laboratory staff and health care providers. Actions the FDA is taking. Instructions for reporting problems with the Alinity m SARS-CoV-2 AMP or Alinity m Resp-4-Plex AMP Kits. Questions? If you have questions about this Letter to Health Care Providers, email COVID19DX@fda.hhs.gov.

Follow us on Twitter at @FDADeviceInfo Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA